AZN's COVID Shot 70% Effective On Average, ARQT Aces Scalp Psoriasis Study, BLRX' BLAST Fizzles

AZN's COVID Shot 70% Effective On Average, ARQT Aces Scalp Psoriasis Study, BLRX' BLAST Fizzles

RTTNews

Published

Today's Daily Dose brings you news about the efficacy of AstraZeneca's COVID-19 vaccine candidate, Arcutis' results from phase IIb trial of ARQ-154 in scalp psoriasis, BioLineRx' BLAST study in acute myeloid leukemia, clinical hold imposed on Bellerophon's Phase III COVID-19 study, Kiniksa's date with FDA, and Merck adding a COVID-19 therapeutic candidate to its pipeline through an acquisition.

Full Article